Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 89

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 89
---
 information or expose us to potential liability;          |
| ● | disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our drug and diagnostics technology candidates, or that result in costly litigation or arbitration that diverts management attention and resources; |
| ● | the collaboration may be terminated and, if terminated, may result the Company needing additional capital to pursue further development or commercialization of the applicable drug and diagnostics technology candidates;                                                                      |
| ● | the collaborator may own or co-own IP covering our drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP;                                                                                                      |
| ● | the collaboration may result in increased operating expenses or the assumption of indebtedness or contingent liabilities; and                                                                                                                                                                   |

| ● | the collaboration arrangement may result in the loss of key personnel and uncertainties in our ability to maintain key business relationships. |

As a result, if we enter into
collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions,
which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction or license, we may not achieve
the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with a suitable collaborator
on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug or diagnostics technology candidate,
reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense.

If we fail to enter into collaborations,
we may seek to fund and undertake development or commercialization activities on our own, but we may not have sufficient funds or expertise
to undertake the necessary development and commercialization activities. In such a case, we may not be able to further develop our drug
and diagnostics technology candidates or bring them to market and generate product sales revenue, which would harm our business prospects,
financial condition and results of operations.

Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.

We are exposed to the risk
of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors.
Misconduct by these parties could